Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: pan-RAF kinases inhibitors - Ipsen

Next Previous
Search
Drug Profile

Research programme: pan-RAF kinases inhibitors - Ipsen

Alternative Names: pan-RAFi/IRICoR

Latest Information Update: 28 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Institute for Research in Immunology and Cancer - Commercialization of Research; University of Montreal
  • Developer Institute for Research in Immunology and Cancer - Commercialization of Research; Ipsen; University of Montreal
  • Class Antineoplastics
  • Mechanism of Action Proto oncogene protein c raf inhibitors; Proto-oncogene protein A-raf inhibitors; Proto-oncogene protein b-raf inhibitors; Raf kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 28 Mar 2025 No recent reports of development identified for preclinical development in Cancer in Canada
  • 15 Feb 2023 Pan-RAF kinases inhibitors licensed to Ipsen worldwide
  • 17 Feb 2021 Preclinical trials in Cancer in Canada (unspecified route), prior to February 2021 (Ipsen pipeline, February 2021)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top